News | April 03, 2022
JBCPL buys Azmarda trademark for India at Rs 246 crore
The brand Azmarda fits well with JBCPL's overall strategy of strengthening its presence in the cardiology segment in India.
The brand Azmarda fits well with JBCPL's overall strategy of strengthening its presence in the cardiology segment in India.
The Cidmus brand shall be affixed on the pharmaceutical composition comprising a combination of Valsartan and Sacubitril (currently under Novartis patent) which is indicated for heart failure patients with reduced ejection fraction
The Congress gathers pharmaceutical companies, CMOs and CDMOs, governmental bodies together with pharmaceutical equipment providers and service companies
Novartis data again demonstrate age-appropriate development when Zolgensma is used presymptomatically, and post-hoc data reveal SMA Type 1 patients could speak, swallow and maintain airway protection
Ritika has also extensively worked with clients such as WHO, GAVI Alliance, USAID, Gilead, Novartis, Sanofi Pasteur
With over 20 years of international leadership experience, Dr. Amrein has led many teams and organizations across over 30 geographies
Haleon will have a portfolio of category-leading brands including Sensodyne, Voltaren, Panadol and Centrum
Appoints Dr Rafiq Hasan as CEO
Danny Bar-Zohar will become Global Head of R&D and Joern-Peter Halle will become Chief Strategy Officer
Aim of the virtual conference is to facilitate Indian Pharma Industry adopt Green & Sustainable Chemistry as a tool to enhance Economic & Environmental Competitiveness
Subscribe To Our Newsletter & Stay Updated
